Microbiological and clinical study of methicillin-resistant Staphylococcus aureus (MRSA) carrying VraS mutation: changes in susceptibility to glycopeptides and clinical significance

International Journal of Antimicrobial Agents

Volumn 31, Issue 1, 2008, Pages 64-70

  Kato, Yoshihisa ^a   Suzuki, Takahisa ^a   Ida, Takashi ^a   Maebashi, Kazunori ^a   Sakurai, Masanori ^b   Shiotani, Joji ^b   Hayashi, Izumi ^c  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

Glycopeptide; MRSA; Susceptibility; Two component regulatory system

Indexed keywords

ANTIINFECTIVE AGENT; COTRIMOXAZOLE; GENE PRODUCT; GLYCOPEPTIDE; HABEKACIN; IMIPENEM; OXACILLIN; RIFAMPICIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN; VRAS PROTEIN;

ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CLINICAL STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL;

AGED; AMINO ACID SUBSTITUTION; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DIBEKACIN; FEMALE; GLYCOPEPTIDES; HUMANS; IMIPENEM; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; OXACILLIN; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 36849052983     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.08.012     Document Type: Article

References (16)

1. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
2. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1 (2001) 147-155
3. Robert J., Bismuth R., and Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 57 (2006) 506-510
4. Kuroda M., Kuroda H., Oshima T., Takeuchi F., Mori H., and Hiramatsu K. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol Microbiol 49 (2003) 807-821
5. Sakoulas G., Eliopoulos G.M., Fowler Jr. V.G., et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 49 (2005) 2687-2692
6. Katayama Y, Kuroda H, Kuroda M, Hiramatsu K. In: 77th General Meeting of the Japanese Society for Bacteriology; 1-3 April 2004; Osaka, Japan. Poster no. 1072.
7. Liu C., and Chambers H.F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 47 (2003) 3040-3045
8. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
9. Gardete S., Wu S.W., Gill S., and Tomasz A. Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob Agents Chemother 50 (2006) 3424-3434
10. Ohta T., Hirakawa H., Morikawa K., et al. Nucleotide substitutions in Staphylococcus aureus strains, Mu50, Mu3, and N315. DNA Res 29 (2004) 51-56
11. Maki H., McCallum N., Bischoff M., Wada A., and Berger-Bachi B. tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 48 (2004) 1953-1959
12. Watanakunakorn C. In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin. J Antimicrob Chemother 25 (1990) 69-72
13. Filice G., Lanzarini P., Orsolini P., et al. Effect of teicoplanin and vancomycin on Staphylococcus aureus ultrastructure. Microbiologica 13 (1990) 231-237
14. Hayashi I. Countermeasure of nosocomocal infection in cancer specialized wards with compromised hosts. Ganchiryo To Shukushu 17 (2005) 173-183 [in Japanese]
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Document M100-S16. Wayne, PA: CLSI; 2006.
16. Wootton M., Walsh T.R., and MacGowan A.P. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 3982-3983